Effects of Switching from Agalsidase Beta to Agalsidase Alfa in 10 Patients with Anderson-Fabry Disease

Anderson-Fabry disease (AFD) is a multiorgan X-linked lysosomal storage disease that particularly affects the heart, kidneys, and cerebrovascular system. Current treatment is enzyme replacement therapy (ERT) with agalsidase beta (Fabrazyme(®), Genzyme Corporation, Cambridge, MA, USA) or agalsidase a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Pisani, A., Spinelli, L., Visciano, B., Capuano, I., Sabbatini, M., Riccio, E., Messalli, G., Imbriaco, M.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3565648/
https://ncbi.nlm.nih.gov/pubmed/23430546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/8904_2012_177
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki